<?xml version='1.0' encoding='utf-8'?>
<document id="24623479"><sentence text="Reduced physiologically-based pharmacokinetic model of repaglinide: impact of OATP1B1 and CYP2C8 genotype and source of in vitro data on the prediction of drug-drug interaction risk."><entity charOffset="55-66" id="DDI-PubMed.24623479.s1.e0" text="repaglinide" /></sentence><sentence text="To investigate the effect of OATP1B1 genotype as a covariate on repaglinide pharmacokinetics and drug-drug interaction (DDIs) risk using a reduced physiologically-based pharmacokinetic (PBPK) model"><entity charOffset="64-75" id="DDI-PubMed.24623479.s2.e0" text="repaglinide" /></sentence><sentence text="" /><sentence text="Twenty nine mean plasma concentration-time profiles for SLCO1B1 c" /><sentence text="521T&gt;C were used to estimate hepatic uptake clearance (CLuptake) in different genotype groups applying a population approach in NONMEM v" /><sentence text="7" /><sentence text="2" /><sentence text="" /><sentence text="Estimated repaglinide CLuptake corresponded to 217 and 113 μL/min/10(6) cells for SLCO1B1 c"><entity charOffset="10-21" id="DDI-PubMed.24623479.s9.e0" text="repaglinide" /></sentence><sentence text="521TT/TC and CC, respectively" /><sentence text=" A significant effect of OATP1B1 genotype was seen on CLuptake (48% reduction for CC relative to wild type)" /><sentence text=" Sensitivity analysis highlighted the impact of CLmet and CLdiff uncertainty on the CLuptake optimization using plasma data" /><sentence text=" Propagation of this uncertainty had a marginal effect on the prediction of repaglinide OATP1B1-mediated DDI with cyclosporine; however, sensitivity of the predicted magnitude of repaglinide metabolic DDI was high"><entity charOffset="76-87" id="DDI-PubMed.24623479.s13.e0" text="repaglinide" /><entity charOffset="114-126" id="DDI-PubMed.24623479.s13.e1" text="cyclosporine" /><entity charOffset="179-190" id="DDI-PubMed.24623479.s13.e2" text="repaglinide" /><pair ddi="false" e1="DDI-PubMed.24623479.s13.e0" e2="DDI-PubMed.24623479.s13.e0" /><pair ddi="false" e1="DDI-PubMed.24623479.s13.e0" e2="DDI-PubMed.24623479.s13.e1" /><pair ddi="false" e1="DDI-PubMed.24623479.s13.e0" e2="DDI-PubMed.24623479.s13.e2" /><pair ddi="false" e1="DDI-PubMed.24623479.s13.e1" e2="DDI-PubMed.24623479.s13.e1" /><pair ddi="false" e1="DDI-PubMed.24623479.s13.e1" e2="DDI-PubMed.24623479.s13.e2" /></sentence><sentence text=" In addition, the reduced PBPK model was used to assess the effect of both CYP2C8*3 and SLCO1B1 c" /><sentence text="521T&gt;C on repaglinide exposure by simulations; power calculations were performed to guide prospective DDI and pharmacogenetic studies"><entity charOffset="10-21" id="DDI-PubMed.24623479.s15.e0" text="repaglinide" /></sentence><sentence text="" /><sentence text="The application of reduced PBPK model for parameter optimization and limitations of this process associated with the use of plasma rather than tissue profiles are illustrated" /><sentence text="" /></document>